 |
| |
Ark Therapeutics Group Plc is a United Kingdom-based company. The principal activity of the Company is the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The Company's product portfolio comprises Kerraboot, Flaminal, Kerraped, Neuropad, Kerramax, Vitor and Trinam. Vitor is an oral, small molecule therapy for the treatment of muscle wasting. Kerraboot is a wound dressing device for leg and foot ulcers. Flaminal is a non-cytotoxic alginate gel with anti-microbial properties utilizing an enzyme system. Kerraped is a medical footwear device for the management of diabetic foot ulcer patients. Neuropad is a screening test for autonomic neuropathy and an early detection test for diabetic foot syndrome. During the year ended December 31, 2008, the Company acquired Lymphatix Oy. Its subsidiary is Ark Therapeutics Oy.
Ark Therapeutics Group plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary
Ark Therapeutics Group plc (Ark Therapeutics) is a healthcare group company engaged in the discovery, development and commercialization of specialist medicine with focuses on vascular disease, wound care and cancer. Its marketed products comprise Kerraboot, Kerraped, Flaminal. The company is headquartered in London, United Kingdom. On 8 Jan 2008, the company acquired all the issued share capital of Lymphatix Oy, a biotechnological company, for a purchase consideration of GBP1.6 million ($3.15 million), including acquisition costs. The company paid GBP1.54 million ($3.03 million) by the issuance of 1,733,657 ordinary shares.
The Ark Therapeutics Group plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company's major recent financial deals.
Scope
- Provides key company information for business intelligence needs
- Gives information on the company's major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company's history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.
Reasons to buy
- A quick "one-stop-shop" to understand the company.
- Support sales activities by understanding your customers' businesses.
- Qualify prospective partners and suppliers.
- Understand and respond to your competitors' business structure, strategy and prospects through.
- Understanding the key deals which have shaped the company.
Ark Therapeutics Group plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile: http://www.companiesandmarkets.com/r.ashx?id=506W0XEMN166546
|
—
